GE Healthcare Acquires PAA Laboratories GmbH

GE Healthcare Acquires PAA Laboratories GmbHGE Healthcare Acquires PAA Laboratories GmbH in a bid to reinforce and strengthen biopharmaceutical manufacture segment of the company.

The company announced today that they have entered a definitive agreement to acquire PAA Laboratories for an undisclosed amount.

“The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally,” said Kieran Murphy, President and CEO of GE Healthcare Life Sciences. “GE Healthcare Life Sciences is well known for its expertise in the “downstream” processes of biopharmaceutical manufacturing. Adding “upstream” capabilities will enable us to provide an end-to-end, fully integrated service to our customers. We believe that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product and reduce time to market.”

GE is upbeat regarding the acquisition of the PIAA acquisition and notes it will expand its offering of products and services for cell biology research and for the discovery and manufacture of biopharmaceuticals including recombinant proteins, antibodies and vaccines.

“The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally,” said Kieran Murphy, President and CEO of GE Healthcare Life Sciences. “GE Healthcare Life Sciences is well known for its expertise in the “downstream” processes of biopharmaceutical manufacturing. Adding “upstream” capabilities will enable us to provide an end-to-end, fully integrated service to our customers. We believe that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product and reduce time to market.”

Lastly, GE Healthcare noted that assuming regulatory concerns pass without a hitch that the acquisition is to close during Q3, 2011.



Latest News

Oppenheimer & Co. Inc. Increases Position in ISHARES TR/0-5 YR TIPS BD ETF
Oppenheimer & Co. Inc. Increases Position in ISHARES TR/0-5 YR TIPS BD ETF
Osborne Partners Capital Management LLC Sells 40,750 Shares of Fortive Corp
Osborne Partners Capital Management LLC Sells 40,750 Shares of Fortive Corp
Tokenbox Price Down 38.2% Over Last 7 Days
Tokenbox Price Down 38.2% Over Last 7 Days
Thompson Investment Management Inc. Has $951,000 Holdings in Black Knight Inc
Thompson Investment Management Inc. Has $951,000 Holdings in Black Knight Inc
LKQ Co.  Stake Boosted by Oppenheimer Asset Management Inc.
LKQ Co. Stake Boosted by Oppenheimer Asset Management Inc.
Takkt Ag  Given Average Rating of “Buy” by Brokerages
Takkt Ag Given Average Rating of “Buy” by Brokerages


© 2006-2019 Ticker Report